€17 million for Kiadis Pharma
Kiadis Pharma, a clinical-stage biopharmaceutical company, today announces that it has closed private placements totalling EUR 17 million with two healthcare focused investors. Kiadis plans to use the proceeds from these transactions to continue to fund the development of the its K-NK-cell therapy programs.
Arthur Lahr, CEO of Kiadis commented, “We are very pleased to have completed these transactions, which together will fund our business through near-term milestones with our K-NK programs that we believe will create value for all stakeholders.”
In April, Kiadis raised EUR 17 million in gross proceeds through two private placements with healthcare-focused investors, both of which closed today. Pursuant to the first EUR 12 million private placement, 7,490,637 new shares were issued at a subscription price of EUR 1.60 per share, and 3,745,318 5-year warrants with an exercise price of EUR 2.22 were granted. Of the new shares, 5,800,000 have been admitted to listing and trading on Euronext Amsterdam and Euronext Brussels as per today. In the context of this private placement, the Company has agreed to a lock-up undertaking not to issue further new shares for a period of 60 calendar days after the settlement date. In the event that the volume weighted average share price has exceeded EUR 2.00 on any trading day during the lock up period, the lock-up restriction shall lapse on the later of the 45th day after the Closing Date and the trading date that the VWAP has exceeded EUR 2.00.
Pursuant to the second EUR 5 million private placement, 2,986,858 new shares were issued at a subscription price of EUR 1.67 per share, and 1,493,429 5-year warrants with an exercise price of EUR 2.32 were granted.
The remaining 1,690,637 new shares related to the first private placement and the 2,986,858 new shares related to the second private placement shall be admitted to listing and trading on Euronext Amsterdam and Euronext Brussels as soon as possible on the basis of a prospectus that the Company shall prepare, get approved by the Netherlands Authority for the Financial Markets (Stichting Autoriteit Financiële Markten) and make generally available in accordance with the Prospectus Regulation (EU) 2017/1129 and which shall be notified to the Belgian Financial Services and Markets Authority (Autorité des services et marchés financiers) for passporting in accordance the Prospectus Regulation.
About Kiadis Pharma’s K-NK-Cell Therapies
Kiadis Pharma’s K-NK platform is designed to deliver potent NK cells to help each patient, without the need for genetic engineering. Kiadis Pharma’s programs consist of off-the-shelf and haploidentical donor NK-cell therapy products for the treatment of liquid and solid tumors as adjunctive and stand-alone therapies.
The Company’s PM21 particle technology enables improved ex vivo expansion and activation of cytotoxic NK cells supporting multiple high-dose infusions. Kiadis Pharma’s proprietary off-the-shelf NK-cell platform is based on NK cells from unique universal donors and can make NK-cell therapy product rapidly and economically available for a broad patient population across a potentially wide range of indications.
Kiadis Pharma is developing K-NK002, which is administered as an adjunctive immunotherapeutic on top of HSCT, and K-NK003 for the treatment of relapse/refractory acute myeloid leukemia. In addition, Kiadis Pharma has pre-clinical programs evaluating NK-cell therapy for the treatment of solid tumors.
Source: Kiadis (press release)